I guess some one did not like the call! I myself thought it was as to be expected. It seems all the bad news is now priced in and hopefully this should be a turning point.
Its normal practice for these companies to short a significant no. of shares at the price they buy. This way if for some reason the price goes down significantly they do not lose a great deal. This weakness in the SP will persist for a few more days until they are fully hedged.
How many of these presentations have you attended?
My two cents.
By and large drugs for BPH long term have an improvement only of 5-6 on the AUS score. By the way NYMOX drug improvement of 10 is not sustained; after some time it drops to 7-8 but is maintained over several months.
Approximately half the patients who take drugs find them non effective and this is where NYMOX will be positioned by physicians. They will try the medications and if they don't work the NYMOX injection before considering surgery. Recordati their partner in Europe is on record (pun intended) they intend to position NYMOX in this niche in their trial.
Every year 4-8 Billion is spent in the US on BPH; if NYMOX can get a fraction of that; they will do well.
I agree with you.
Paul took $ 2 million out, which in the scheme of things is not a huge amount and could be for any reason. If he wanted to sell a bigger chunk, I assume he could have sold it to Lorryse Greyse or whatever their name is and nobody could have done anything about it.
Looking at the trials and the study although I fault management on a lot of things; they are not skimping on the trials themselves. The number of subjects is enough to get a definite idea whether the drug works or not. This seems to imply confidence in the drug
After a lot of deliberation I think I am going to stay invested but if he does it again then this line of reasoning does not hold and I will be out.
Something I came across at the John Hopkins website and I have seen similar data in other places suggesting drugs are ineffective in approximately half the men who take them. Leaves plenty of patients for NYMOX if and when they get their trials completed and if the dug works.
Drug treatment of BPH is a new development, and data is still being gathered on the benefits and possible adverse effects of longterm therapy. Currently, two types of drugs-5-alpha-reductase inhibitors and alpha-adrenergic blockers-are used to treat BPH. Preliminary research suggests that these drugs improve symptoms in 30 to 60% of men taking them, but it is not yet possible to predict who will respond to medical therapy, or which drug will be better for an individual patient.
I did find an answer to one of my questions, improvement in Qmax. There is a presentation on Google from 2008 by who else but our Dr. Shore quoting an improvement in Qmax of 2.79 in patients on NX-1207 with no details. This improvement in Q max is what medications such as Flomax give you ( between a 2-3 point improvement)
I have three questions that are puzzling me, maybe some one on the board has more information and can enlighten me.
Looking at other companies FDA trails I see AUASI or a similar score is reported and I see that in the NYMOX press releases. The other important parameter is Qmax or the maximal urinary flow and its important to show an increase in it for approval and I do not see it being mentioned in the NYMOX press releases.
Secondly I have not seen one single peer reviewed publication apart fro the PR nonsense from its paid consultant.
Thirdly Lorryse Grayse or whatever their name is has been buying shares for several years but I do not see them listed as a 5% holder. Why?
Anyone have explanations for any of this?
On the other hand whoever gave him two million must have done his due diligence before handing him the money; especially if he can not sell for four months (I do not know if this is true).
I think the reason they are going slow on it is to save money; its not a phase three trial so will not help with FDA approval.
I agree with most of what you said.
What I find morally objectionable is the doctor telling us all the time he has not sold a single share ever and then wrecking the share price with his amateurish and ill timed sale with no warning. Then he issues a statement he has no idea why the stock is down. He has lost whatever little trust he had. This is a big deal and I think saying no sweat he just needed the money does not sit well.
20 million is not a doctors salary its a lifetime of earnings for most physicians.
1.4% of ownership in company is not insignificant. Denying any knowledge of reason for stock price fall is morally fraud; although I am sure the doctor covered his #$%$ in the legal phraseology he used.
The fact that we shareholders can not do anything about is sad but this is no occasion for cheerleading. After this now all we need is pisserpumper and his alias animal #$%$ to come out with a love letter to the doctor.
When the stock was tanking; they come out with a statement that they were unaware of the reason why it was sellingg off and it was tanking becuase the company owner who claimed to have nver sold a single share of his stock was selling. Someone should call the SEC!
He was supposed to own 50% of the company; now he owns 34%; where did the remaining shares go? This does not add up. Something is not right here.
For the last several days we have increased volume with some increase in the share price. I was wondering if this was from Europe subsequent to the Milan presentation but European markets were closed today and the same thing happened; so looks like the buying is from here.
I checked before I posted the question and did not see it at clinical trails.gov. I think I will call the company and ask.
I came across some of your previous postings on the placebo question which has been bothering me. If I may ask where did you get the information on the proposed statistical analysis being intent to treat? Thanks.
There is no analyst coverage; its flying under the radar. It is a genuine company although a one man show and a very speculative investment . If the current phase three does not pan out; the company is dust.
The study will not be completed by May; the above is a piece of trash from a garbage stock touting company; which is faithfully regurgitated by the long term lotus eaters on this board. As per NYMOX latest press release the trial is currently only half recruited.